News

Filter

Current filters:

Eisai

1 to 9 of 882 results

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

Eisai's lenvatinib shows statistically-significant progression-free survival in Ph III trial

13-02-2015

Japanese drug major Eisai has published results of its SELECT Phase III study, showing its lenvatinib…

EisaiHealthJapanlenvatinibPharmaceuticalWeakness

Helsinn grants Stendhal rights to NEPA in several Latin America countries

02-02-2015

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos…

AkynzeoEisaiHelsinnLicensingNEPAnetupitantOncologypalonosetronPharmaceuticalSouth AmericaStendhal

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

German Federal Joint Committee confirms 'considerable' benefit of Eisai's Halaven in breast cancer

23-01-2015

The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese…

EisaiGermanyHalavenOncologyPharmaceuticalRegulation

Eisai launches epilepsy treatment Exalief in Russia

Eisai launches epilepsy treatment Exalief in Russia

20-01-2015

Japanese drug major Eisai has announced that epilepsy drug Exalief (eslicarbazepine acetate) will soon…

EisaiExaliefMarkets & MarketingNeurologicalPharmaceuticalRussia

Helsinn settles with Sandoz over Aloxi in USA

12-01-2015

Privately-held Swiss cancer specialist Helsinn Group say it has entered into a settlement agreement with…

AloxiEisaiGenericsHelsinn GroupLegalNovartisOncologyPatentsSandozUSA

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

Eisai's Fycompa for refractory partial-onset seizures meets Phase III trial primary endpoint

05-01-2015

Japanese drug major Eisai has announced a Phase III trial of antiepileptic drug Fycompa (perampanel)…

EisaiFycompaJapanNeurologicalperampanelPharmaceuticalResearch

Eisai's Halaven now available in Russia for advanced breast cancer

Eisai's Halaven now available in Russia for advanced breast cancer

18-12-2014

Halaven (eribulin) manufactured by Japanese drug major Eisai is now available in Russia.

EisaiHalavenOncologyPharmaceuticalRegulationRussia

1 to 9 of 882 results

COMPANY SPOTLIGHT

Menarini

Back to top